A new standard of care for advanced lung cancer: what’s next for pembrolizumab?
Key messages from the SCLC session at NCRI 2016
Nausea and vomiting risk factors
Trial results of vemurafenib, cobimetinib and LDH as a predictive marker in BRAF-mutated melanoma
Characterizing a phenomenon in GBM patients who do not respond well to immunotherapy